[go: up one dir, main page]

AR130115A2 - STABLE PROTEIN SOLUTION FORMULATION CONTAINING A HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY - Google Patents

STABLE PROTEIN SOLUTION FORMULATION CONTAINING A HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY

Info

Publication number
AR130115A2
AR130115A2 ARP230102051A ARP230102051A AR130115A2 AR 130115 A2 AR130115 A2 AR 130115A2 AR P230102051 A ARP230102051 A AR P230102051A AR P230102051 A ARP230102051 A AR P230102051A AR 130115 A2 AR130115 A2 AR 130115A2
Authority
AR
Argentina
Prior art keywords
high concentration
antibody
protein solution
formulation containing
vegf antibody
Prior art date
Application number
ARP230102051A
Other languages
Spanish (es)
Inventor
Huixang Zhang
Charles Boring
Alok Kulshreshtha
Yuhong Zeng
Li Wan
Laman Alani
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR130115A2 publication Critical patent/AR130115A2/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona anticuerpos anti-VEGF formulados como composiciones farmacéuticas acuosas, de alta concentración, adecuados para una inyección, preferentemente una inyección intravítrea. Las composiciones farmacéuticas acuosas son útiles para la administración de una alta concentración del ingrediente activo del anticuerpo a un paciente sin altos niveles de agregación de anticuerpo y sin un alto nivel de materia particulada subvisible. Una composición acuosa de la invención comprende un anticuerpo que tiene una concentración de al menos 50 mg/ml. Una composición farmacéutica acuosa de la invención incluye azúcar, un agente de amortiguación y un tensioactivo.The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions suitable for injection, preferably intravitreal injection. The aqueous pharmaceutical compositions are useful for administration of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of subvisible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the invention includes sugar, a buffering agent and a surfactant.

ARP230102051A 2014-11-07 2023-08-03 STABLE PROTEIN SOLUTION FORMULATION CONTAINING A HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY AR130115A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462076770P 2014-11-07 2014-11-07
US202062088061P 2020-12-05 2020-12-05

Publications (1)

Publication Number Publication Date
AR130115A2 true AR130115A2 (en) 2024-11-06

Family

ID=93840427

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230102051A AR130115A2 (en) 2014-11-07 2023-08-03 STABLE PROTEIN SOLUTION FORMULATION CONTAINING A HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY

Country Status (1)

Country Link
AR (1) AR130115A2 (en)

Similar Documents

Publication Publication Date Title
GT201700096A (en) STABLE PROTEIN FORMULATION IN SOLUTION CONTAINING A HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY
CY1122181T1 (en) PHARMACEUTICAL FORM OF ANTIBODY
TN2014000431A1 (en) Antibody formulatoin
CL2021001587A1 (en) Protein solution formulation containing a high concentration of an anti-vegf antibody
MX2019014666A (en) Pharmaceutical composition comprising c-met antibody-drug conjugate and use thereof.
AR130115A2 (en) STABLE PROTEIN SOLUTION FORMULATION CONTAINING A HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY
AR102572A1 (en) FORMULATION OF STABLE PROTEIN SOLUTION CONTAINING HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY